Improved Progression-Free Survival (PFS) of Alemtuzumab (Campath®, MabCampath®) Plus Fludarabine (Fludara®) Versus Fludarabine Alone as Second-Line Treatment of Patients with B-Cell Chronic Lymphocytic Leukemia: Preliminary Results From a Phase III Randomized Trial.

Andreas Engert,Liana Gercheva,Tadeusz Robak,Pilipenko Galina,Jingyang Wu,Cynthia A Sirard,Thomas Elter

doi:10.1182/blood.v114.22.537.537

Improved Progression-Free Survival (PFS) of Alemtuzumab (Campath®, MabCampath®) Plus Fludarabine (Fludara®) Versus Fludarabine Alone as Second-Line Treatment of Patients with B-Cell Chronic Lymphocytic Leukemia: Preliminary Results From a Phase III Randomized Trial.

Andreas Engert, Liana Gercheva + Show 5 more

https://doi.org/10.1182/blood.v114.22.537.537

Copy DOI

Export

Save

Cite

Journal: Blood	Publication Date: Nov 20, 2009
Citations: 6

Affiliation: University of Cologne, University Specialized Hospital for Active Treatment of Endocrinology, Medical University of Lodz, Cherkasy State Technological University, SynZyme Technologies (United States)

#Maximum Lymph Node Size #Genzyme Corporation #Refractory Chronic Lymphocytic Leukemia #Advisory Committees #Second-line Therapy For Pts #Entity's Board #2nd Interim Analysis #Research Funding #Higher Overall Response #Board Of Directors

Abstract
Full-Text
Similar Papers

Abstract

Listen

Improved Progression-Free Survival (PFS) of Alemtuzumab (Campath®, MabCampath®) Plus Fludarabine (Fludara®) Versus Fludarabine Alone as Second-Line Treatment of Patients with B-Cell Chronic Lymphocytic Leukemia: Preliminary Results From a Phase III Randomized Trial.

Full Text

Published Version

Check institute access

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Blood

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

Improved Progression-Free Survival (PFS) of Alemtuzumab (Campath®, MabCampath®) Plus Fludarabine (Fludara®) Versus Fludarabine Alone as Second-Line Treatment of Patients with B-Cell Chronic Lymphocytic Leukemia: Preliminary Results From a Phase III Randomized Trial.